Abstracts Archive - Page 861 of 2425 - ACR Meeting Abstracts

Abstract Number: 1539 • 2019 ACR/ARP Annual Meeting
Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Laure Gossec¹, Stefan Siebert ², Paul Bergmans ³, Kurt De Vlam ⁴, Elisa Gremese ⁵, Beatriz Joven-Ibáñez ⁶, Ellie Korendowych ⁷, Tatiana Korotaeva ⁸, Wim Noël ⁹, Michael Nurmohamed ¹⁰, Christophe Richez ¹¹, Petros Sfikakis ¹², Pavel Smirnov ¹³, Elke Theander ¹⁴ and Josef Smolen ¹⁵, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Royal National Hospital for Rheumatic Diseases, Bath, Bath, United Kingdom, ⁸Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁹Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ¹⁰Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹¹Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ¹²Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹³Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹⁴Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis strongly impacts patients’ quality of life (QoL). Insights on the effects of biologic treatments on different domains of health-related QoL in a…
Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 1541 • 2019 ACR/ARP Annual Meeting
Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis
Keith Betts ¹, Pankaj Patel², Jinlin Song ¹, Jing Zhao ³, Yan Wang ¹, Jenny Griffith ² and Eric Wu ⁴, ¹Analysis Group, Inc., Los Angeles, CA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Denver, CO, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Clinical studies have shown that a large proportion of psoriatic arthritis (PsA) patients treated with apremilast failed to achieve improved physical function or experienced…
Abstract Number: 1542 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Proton Rahman ¹, Derek Haaland ², Dalton Sholter ³, Michael Starr ⁴, Arthur Karasik ⁵, Michelle Teo ⁶, Sanjay Dixit ⁷, Ariel Masetto ⁸, Anna Jaroszynska ⁹, Pauline Boulos ⁷, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Waterside Clinic, Barrie, ON, Canada, ³Rheumatology Associates, Edmonton, AB, Canada, ⁴Montreal General Hospital, Montreal, QC, Canada, ⁵., Toronto, ON, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹., Oakville, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trial and usually varies over time. The purpose…
Abstract Number: 1543 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Regan Arendse ², Isabelle Fortin ³, Andrew Chow ⁴, Majed Khraishi ⁵, Suneil Kapur ⁶, Michel Zummer ⁷, Raheem Kherani ⁸, Jonathan Chan ⁹, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵Nexus Clinical Research, Memorial University of Newfoundland, St. Johns, NL, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁸University of British Columbia, Richmond, BC, Canada, ⁹Artus Health Clinic, Vancouver, BC, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose of…
Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Ariel Masetto ², Michelle Teo ³, Pauline Boulos ⁴, Dalton Sholter ⁵, Suneil Kapur ⁶, Emmanouil Rampakakis ⁷, Meagan Rachich ⁸, Odalis Asin-Milan ⁸, Allen Lehman ⁸ and Francois Nantel⁸, ¹Memorial University, Newfoundland, NL, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷JSS Medical Research, Montreal, Canada, ⁸Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
Abstract Number: 1545 • 2019 ACR/ARP Annual Meeting
Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)
Jessica Walsh¹, Marina Magrey ², Uta Kiltz ³, Xenofon Baraliakos ⁴, Maggie Weng ⁵, Theresa Hunter ⁶, Xiaoqi Li ⁶, Luis Leon ⁷, David Sandoval ⁷ and Kentaro Inui ⁸, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵National Cheng-Kung University Medical Center, Tainan, Taiwan (Republic of China), ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Previous studies have determined that axial spondyloarthritis (axSpA) significantly impairs patients’ health-related quality of life (HRQoL).1 The patients with nr-axSpA have the same disease…
Abstract Number: 1546 • 2019 ACR/ARP Annual Meeting
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Ennio Giulio Favalli ¹, Antonio Marchesoni ¹, Silvia Balduzzi ², Carlomaurizio Montecucco ³, Claudia Lomater ⁴, Gloria Crepaldi ⁴, Silvia Tamanini ⁵, Chiara Bazzani ⁶, Enrico Fusaro ⁷, Marta Priora ⁷, Aurora Ianniello ⁸ and Roberto Caporali¹, ¹University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ²Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Lombardia, Italy, ³Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁴AO Ordine Mauriziano, SSD Reumatologia, Torino, Turin, Piemonte, Italy, ⁵ASST Spedali Civili and University of Brescia, Milan, Lombardia, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷A.O.U. Città della Salute e della Scienza di Torino, SC Reumatologia, Turin, Piemonte, Italy, ⁸Day Hospital Multidisciplinare PO SS. Trinità, Borgomanero, Borgomanero, Piemonte, Italy
Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the…
Abstract Number: 1547 • 2019 ACR/ARP Annual Meeting
Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials
Uta Kiltz¹, Désirée van der Heijde ², Annelies Boonen ³, Lianne Gensler ⁴, Theresa Hunter ⁵, Fangyi Zhao ⁶, Baojin Zhu ⁵, Rebecca Bolce ⁵, Hilde Carlier ⁵ and Jürgen Braun ⁷, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴University San Francisco California, San Francisco, CA, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) measures health, disability, and functioning in patients (pts) with spondyloarthritis (SpA)[1,2]. The purpose of…
Abstract Number: 1548 • 2019 ACR/ARP Annual Meeting
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Carolina Merino Argumanez¹, Valentina Emperiale ², María Martín ³, Marta Valero ⁴, javier Bachiller ⁵, Beatriz Joven-Ibáñez ⁶, Ana Pérez-Gómez ⁷ and Jose Campos ¹, ¹Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ³Hospital Universitario Doce de Octubre, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Background/Purpose: Secukinumab is a newly introduced biologic therapy against IL-17 which has been proved effective in patients with ankylosing spondylitis (AS) in clinical trials and…
Abstract Number: 1549 • 2019 ACR/ARP Annual Meeting
Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
Cheng-Chung Wei¹, Lianne Gensler ², Jessica Walsh ³, Robert B.M. Landewé ⁴, Tetsuya Tomita ⁵, Fangyi Zhao ⁶, Gaia Gallo ⁶, Hilde Carlier ⁷ and Maxime Dougados ⁸, ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²University San Francisco California, San Francisco, CA, ³Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Hôpital Cochin, Paris, France
Background/Purpose: During 16 weeks of blinded treatment, ixekizumab (IXE) and an adalimumab (ADA) active reference arm were found superior to placebo (PBO) in improving signs…
Abstract Number: 1550 • 2019 ACR/ARP Annual Meeting
Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
Anthony Turkiewicz¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², So Young Park ² and Arnaud Constantin ³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: While the composite ACR core data set is considered a standard for assessing disease severity and improvement in PsA, understanding the response rates of…
Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Lykke Midtbøll Ørnbjerg ¹, Cecilie Heegaard Brahe¹, Anne Gitte Loft ², Johan Askling ³, Adrian Ciurea ⁴, Herman Mann ⁵, Servet Akar ⁶, Eirik Kristianslund ⁷, Dan Nordström ⁸, Maria José Santos ⁹, Catalin Codreanu ¹⁰, Manuel Pombo-Suarez ¹¹, Ziga Rotar ¹², Bjorn Gudbjornsson ¹³, Daniela DiGuiseppe ¹⁴, Michael J. Nissen ¹⁵, Karel Pavelka ⁵, Soner Senel ¹⁶, Joe Sexton ¹⁷, Kari K. Eklund ¹⁸, Anabela Barcelos ¹⁹, Ruxandra IONESCU ²⁰, Carlos Sánchez-Piedra ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Irene van der Horst-Bruinsma ²⁴, Gary Macfarlane ²⁵, Florenzo Iannone ²⁶, Brigitte Michelsen ¹, Lise Hyldstrup ²⁷, Niels Steen Krogh ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹¹Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ¹²UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ¹⁵University Hospital Geneva, Geneva, Switzerland, ¹⁶Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁸ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹⁹Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²⁰SPITALUL CLINIC SFANTA MARIA, Bucharest, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸Zitelab / DANBIO, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…
Abstract Number: 1552 • 2019 ACR/ARP Annual Meeting
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study
Philip Mease¹, M. Elaine Husni ², Soumya Chakravarty ³, Shelly Kafka ⁴, Diane Harrison ⁵, Dennis Parenti ⁴, Lilianne Kim ⁵, Kim Hung Lo ⁵, Elizabeth Hsia ⁶ and Arthur Kavanaugh ⁷, ¹Swedish Med Center & U of Wash School of Med, Seattle, WA, ²Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) with active psoriatic arthritis (PsA). Clinically meaningful improvements in…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].